Human mesenchymal stem cells lose their functional properties after paclitaxel treatment.

about

Human mesenchymal stem cells lose their functional properties after paclitaxel treatment.

Item

http://www.wikidata.org/entity/Q49166619

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Human mesenchymal stem cells lose their functional properties after paclitaxel treatment.

@en

Human mesenchymal stem cells lose their functional properties after paclitaxel treatment.

@nl

type

Item

label

Human mesenchymal stem cells lose their functional properties after paclitaxel treatment.

@en

Human mesenchymal stem cells lose their functional properties after paclitaxel treatment.

@nl

prefLabel

Human mesenchymal stem cells lose their functional properties after paclitaxel treatment.

@en

Human mesenchymal stem cells lose their functional properties after paclitaxel treatment.

@nl

P1476

Human mesenchymal stem cells lose their functional properties after paclitaxel treatment.

@en

P2093

Franziska Münz

http://www.w3.org/2001/XMLSchema#string

Klaus-Josef Weber

http://www.w3.org/2001/XMLSchema#string

Nils H Nicolay

http://www.w3.org/2001/XMLSchema#string

Patrick Wuchter

http://www.w3.org/2001/XMLSchema#string

Peter E Huber

http://www.w3.org/2001/XMLSchema#string

Rainer Saffrich

http://www.w3.org/2001/XMLSchema#string

Ramon Lopez Perez

http://www.w3.org/2001/XMLSchema#string

Sonevisay Sisombath

http://www.w3.org/2001/XMLSchema#string

Thuy Trinh

http://www.w3.org/2001/XMLSchema#string

P2860

Radio-resistant mesenchymal stem cells: mechanisms of resistance and potential implications for the clinic

Dexamethasone and azathioprine promote cytoskeletal changes and affect mesenchymal stem cell migratory behavior

Multilineage potential of adult human mesenchymal stem cells

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

Human mesenchymal stem cells are resistant to Paclitaxel by adopting a non-proliferative fibroblastic state

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Managing taxane toxicities.

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

Human mesenchymal stem cells: a bank perspective on the isolation, characterization and potential of alternative sources for the regeneration of musculoskeletal tissues.

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

P304

312

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-017-18862-1

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jürgen Debus

P577

2018-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29321693

http://www.w3.org/2001/XMLSchema#string

P932

5762916

http://www.w3.org/2001/XMLSchema#string